Year: 2023

HIGHfield_logo_horizontal_FINAL_English_28329

HighField Biopharmaceuticals Receives US FDA IND Clearance for Phase 1 Trial of Immunoliposome HF158K1 for Treatment of HER2 low and HER2+ Cancers

The company’s groundbreaking drug encapsulated immunoliposomes may represent a significant improvement over existing antibody drug conjugates HANGZHOU, China--(BUSINESS WIRE)--HighField Biopharmaceuticals...

news_6

CORRECTING and REPLACING Senju Pharmaceutical and Novaliq Enter Into License Agreement For NOV03 (Perfluorohexyloctane Ophthalmic Solution) For the Treatment of Dry Eye Disease in Japan

OSAKA, Japan & HEIDELBERG, Germany & CAMBRIDGE, Mass.--(BUSINESS WIRE)--#NOV03--Fifth paragraph, the number in the quote should read: 10 million units...

news_6

Senju Pharmaceutical and Novaliq Enter Into License Agreement For NOV03 (Perfluorohexyloctane Ophthalmic Solution) For the Treatment of Dry Eye Disease in Japan

OSAKA, Japan & HEIDELBERG, Germany & CAMBRIDGE, Mass.--(BUSINESS WIRE)--#NOV03--Senju Pharmaceutical Co., Ltd., a researched-based Japanese pharmaceutical company focusing the field...